1. Introduction {#sec0005}
===============

Extraskeletal myxoid chondrosarcoma (EMC) is a rare tumour of uncertain differentiation first described by Stout and Verner in 1953 [@bib0005], [@bib0010]. The clinicopathological features of this sarcoma were not described until 1972 by Enzinger and Shiraki [@bib0015]. EMC has shown to have the recurrent balanced chromosomal translocation t(9;22) (q22;q12.2), which leads to the oncogenic fusion gene EWSR1-NR4A3 [@bib0020]. This chimeric gene activates the transcription of target genes involved in cell proliferation and has been detected in approximately 65% of the cases [@bib0025]. Histologically, EMC has a marked phenotypic plasticity that overlaps with mesenchymal malignancies, vague resemblance to human cartilage and an uncertain histiogenesis [@bib0030]. Immunohistochemical studies in most EMC are positive for vimentin and focally positive for S100 protein [@bib0035]. This sarcoma predominantly affects men beyond their fifth decade and normally does not behave in an aggressive way, nevertheless it has a high rate of local recurrence and distant metastases [@bib0025]. The deep thigh is the most common location of EMC, although it can be found in the hands, retroperitoneum, head or neck [@bib0035]. An EMC arising from the lung is extremely infrequent and isolated to case reports in the literature [@bib0035]. We present a case of pulmonary extraskeletal myxoid chondrosarcoma in a 69-year-old male patient that presented with intermittent hemoptysis. This article includes the information available in the world literature but do to it's rarity most of this information comes from isolated case reports. This case report follows the CARE criteria [@bib0040].

2. Case report {#sec0010}
==============

We present a 69-year-old male patient with a past medical history of hypertension. During the last six months, he experienced intermittent hemoptysis without any other symptom. An otolaryngologist explored the patient and initiated treatment for gastroesophageal reflux disease. In the last month, the patient presented hemoptysis daily so he decided to get a CT scan of the chest. The chest CT showed a solid, multilobulated mass of approximately 35 mm on its greater axis located in the right lung (inferior lobe). There was no other pertinent history. Physical examination was normal. A PET/CT scan showed a hypermetabolic solid mass with lobulated borders of approximately 29 × 26 mm located in the lateral segment of the inferior right lobe ([Fig. 1](#fig0005){ref-type="fig"}).

A right thoracotomy with inferior lobectomy and lymphadenectomy of levels VII, VIII, X, and XI levels was performed ([Fig. 2](#fig0010){ref-type="fig"}). Lymphadenectomy was performed because our preoperative presumptive diagnosis was an adenocarcinoma of the lung. The right inferior lobe was extracted with a tumour of approximately 3 × 3 cm ([Fig. 3](#fig0015){ref-type="fig"}). The neoplasm was constituted by cords of small cells with small round nucleus and scarce cytoplasm immerse in an abundant myxoid matrix ([Fig. 4](#fig0020){ref-type="fig"}, [Fig. 5](#fig0025){ref-type="fig"}). The immunophenotype was positive for MUM-1, CDK4, MDM2, and showed focal expression for S-100 protein and CD56. The surgical margins were negative for malignancy. The final pathology report revealed a pulmonary extraskeletal mixoid chondrosarcoma.

After discussing the case in our multidisciplinary tumour board, no further surgical intervention or adjuvant therapy was recommended. The patient will have a close follow up. There is no evidence of persistent o recurrent disease at six months post-surgery.

3. Discussion {#sec0015}
=============

Extraskeletal myxoid chondrosarcoma (EMC) is a malignant neoplasm characterized by the multinodular growth of primitive chondroid cells in an abundant myxoid matrix [@bib0045]. EMC is categorized as a tumour of uncertain differentiation by the 2002 WHO classification and accounts for approximately three percent of all soft tissue sarcomas [@bib0010], [@bib0020]. EMC is characterized by the presence of various chromosomal translocations that result in abnormal gene products that affect cellular proliferation and differentiation and ultimately lead to tumorigenesis [@bib0020]. The typical translocation found in EMC is t(9;22)(q22;q11), which results in the juxtaposition of the gene EWSR1 on chromosome 22 and the gene NR4A3 on chromosome 9 [@bib0030]. The fusion gene EWSR1-NR4A3 has not been detected in any other type of cancer and seems to constitute a pathognomonic EMC marker [@bib0005]. The translocation t(9;22)(q22;q11) is found in approximately 75% of EMC's cases [@bib0050]. Alternative translocations found in EMC are t(9;17)(q22;q11) coding for NR4A3-TAF15 and t(9;15)(q22;q21) coding for NR4A3-TCF12/HTF4 [@bib0030]. Immunophenotypically, EMC shows strong vimentin expression, focal S-100 protein expression, and frequently class III β-tubulin and microtubule-associated protein-2 expression, which are known to be restricted to neural cells [@bib0025].

The differential diagnosis for EMC include myoepithelial carcinoma of soft tissue (MEC), myxoid type of malignant fibrous histiocytoma, myxoid liposarcoma, mixed tumour of soft tissue, nodular fasciitis, ganglion cyst, chordoma, myxoid peripheral nerve sheath tumour, and when arising from the lungs primary pulmonary myxoid sarcoma (PPMS) [@bib0005], [@bib0055], [@bib0060]. The histological features of EMC partially overlap with PPMS and they occasionally share focal EMA and S-100 expresion [@bib0055]. PPMS is characterized by the presence of the chromosomal translocation t(2;22)(q33;q12), which encodes the oncogenic fusion gene EWSR1-CREB1, while EMC is known to express the chimeric gene EWSR1-NR4A3 [@bib0055]. MEC and EMC arise predominantly in the proximal lower extremity and it́s difficult to morphologically distinguish them since they both exhibit features typically seen in myoepithelial tumors [@bib0060]. MEĆs peak incidence is the fourth decade of life, while EMC frequently arises in the sixth decade [@bib0060]. MEC are normally located more superficially than EMC and demonstrate a more aggressive behaviour [@bib0060].

The average age of occurrence of EMC is around 50 years and has a male: female ratio of 2: 1 [@bib0025], [@bib0030], [@bib0065]. In [Table 1](#tbl0005){ref-type="table"}, we state the gender and age preferences of EMC from ten case series published between 2000 and 2014. EMC usually presents as a slow growing palpable mass that causes local pain or tenderness [@bib0025]. EMC is located in the lower extremities in approximately 62% of the cases, in the upper extremities in 17% of the cases, and in the abdomen, retroperitoneum, pelvis, or other locations in 21% of the cases [@bib0070]. [Table 2](#tbl0010){ref-type="table"} presents the location, size, and metastases at time of diagnosis of EMC in ten case series. The majority of EMC has a prolonged clinical course with a 10-year survival rate ranging between 65% and 85%, and a 15-year survival rate of 58%. A 40% risk of distant metastases at 10 years has been documented [@bib0075], [@bib0080]. On [Table 3](#tbl0015){ref-type="table"} we present the clinical follow up of ten EMĆs case series. Despite showing an indolent long term course, EMC has a high potential for local recurrence and distant metastasis and should be considered as an intermediate-grade rather than a low-grade neoplasm [@bib0020], [@bib0030].

The diagnosis of EMC can be confirmed by demonstrating the presence of the pathognomonic translocation t(9;22)(q22;q11), which results in the fusion gene EWSR1-NR4A3 [@bib0005], [@bib0050]. We reviewed the data from different case series regarding the presence of EWSR1-NR4A3 gene rearrangement and the immunohistochemical findings of EMC and presented it on [Table 4](#tbl0020){ref-type="table"}. Contrast enhanced CT show primary EMC as isodense to slightly hypodense to muscle with no internal calcifications [@bib0070]. On MRI, EMC is characterized by multi-nodular soft-tissue masses with hyper-signal intensity on T2 and heterogeneous enhancement after administration of contrast material [@bib0070], [@bib0085]. EMC expressing the fusion gene EWSR1-NR4A3 show peripheral enhancement on MR more frequently than those with other cytogenetic variants [@bib0085]. MRI is preferred over CT for detection of primary disease or local recurrence because of its ability to differentiate the neoplasḿs tissue from unaffected muscle [@bib0070].

Surgical intervention is the only satisfactory chance of cure for EMC [@bib0030]. The use of radiotherapy for this malignancy has not been well defined but it can be considered in an adjuvant setting or for palliation of metastatic disease [@bib0020]. The use of chemotherapeutic agents in the treatment of EMC is controversial and none has demonstrated a durable efficacy [@bib0030]. Stacchiotti et al. reported that anthracycline-based chemotherapy is active in a distinct proportion against EMC and can be used in case of advanced and progressive disease [@bib0075]. The use of tirosin-kinase inhibitors like Sunitinib may also have a role in the treatment of EMC, nevertheless there is not enough evidence at the time [@bib0080]. [Table 5](#tbl0025){ref-type="table"} presents the treatments used for EMC in seven case series.

Pulmonary extraskeletal myxoid chondrosarcomas are extremely rare with only isolated case reports found in the literature [@bib0035]. The lung is the most frequent site of EMĆs metastases [@bib0090]. EMC of the lung may present as an asymptomatic mass or with hemoptysis, dyspnea or anemia [@bib0090], [@bib0095], [@bib0100]. The treatment and prognosis regarding EMC of the lung can only be extrapolated from other cartilaginous tumour types because of the lack of good evidence in literature [@bib0035]. We found four cases of pulmonary extraskeletal myxoid chondrosarcoma in the literature and presented them in [Table 6](#tbl0030){ref-type="table"}.

3. Conclusion {#sec0020}
=============

EMC is a tumour of uncertain differentiation first described in 1953 by Stout and Verner. This malignant neoplasm is characterized by the multinodular growth of primitive chondroid cells in an abundant myxoid matrix. This tumor is characterized by the translocation t(9;22)(q22;q11) which encodes for the fusion gene EWSR1-NR4A3. This translocation is pathognomonic for EMC and is present in approximately 75% of the cases. EMC has a predilection for male patients and its peak incidence is in the sixth decade of life. The usual location for EMC is the lower extremities, in 62% of the cases, followed by the upper extremities, abdomen, retroperitoneum, and pelvis. This sarcoma is classified as an intermediate-grade neoplasm and is characterized by a long clinical course with high potential for local recurrence and distant metastasis. Non-surgical treatment for EMC is usually reserved for recurrent or metastatic disease. Pulmonary extraskeletal myxoid chondrosarcoma is an extremely rare neoplasm with only isolated case reports found in the literature.
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![PET/CT scan showing a hypermetabolic solid mass located in the lateral segment of the inferior right pulmonary lobe.](gr1){#fig0005}

![Right thoracotomy with inferior pulmonary lobectomy and lymphadenectomy of the VII, VIII, X, and XI levels.](gr2){#fig0010}

![Right inferior pulmonary lobe with a mass of approximately 3 × 3 cm.](gr3){#fig0015}

![Hematoxylin and eosin staining.](gr4){#fig0020}

![Masson\'s trichrome staining.](gr5){#fig0025}

###### 

Characteristics of patients with EMC diagnosis in ten case series.

Table 1

  Case Series Author              Publication Year   Number of Cases   Male   Female   Mean Age   Age Range
  ------------------------------- ------------------ ----------------- ------ -------- ---------- -----------
  Oliveira et al. [@bib0015]      2000               23                11     12       50         22--78
  Kawaguchi et al. [@bib0045]     2003               42                20     22       52.1       21--82
  Tateishi et al. [@bib0085]      2006               19                12     7        53         16--76
  Ehara et al. [@bib0010]         2007               4                 3      1        55.5       44--74
  Xiu-feng et al. [@bib0025]      2008               9                 7      2        52.8       31--69
  Drilon et al. [@bib0030]        2008               86                57     29       49.5       15--82
  Ogura et al. [@bib0025]         2012               23                10     13       58         35--79
  Flucke et al. [@bib0055]        2012               5                 3      2        57         37--82
  Stacchiotti et al. [@bib0070]   2013               11                9      2        52         38--69
  Kapoor et al. [@bib0065]        2014               13                10     3        54         29--73

###### 

Size, location, and presence of metastatic disease at time of diagnosis of EMC in ten case series.

Table 2

  Case Series Author              Number   Size (cm)   Location    Metastasis                               
  ------------------------------- -------- ----------- ----------- ------------- ------------- ---- --- --- ----
                                                                   Extremities   Extremities                
  Oliveira et al. [@bib0015]      23       9.5         1.5--18.5   19            2             2    0   0   3
  Kawaguchi et al. [@bib0045]     42       7           1.5--20     28            7             7    0   0   7
  Tateishi et al. [@bib0085]      19       8.9         2--20       15            3             1    0   0   1
  Ehara et al. [@bib0010]         4        NA          NA          3             1             0    0   0   0
  Xiu-feng et al. [@bib0025]      9        7           4--11       7             1             1    0   0   0
  Drilon et al. [@bib0030]        86       6.8         1--30       53            15            11   0   7   10
  Ogura et al. \[4\]              23       7.8         3--18       14            2             7    0   0   3
  Flucke et al. [@bib0055]        5        8.5         1--15       3             1             1    0   0   1
  Stacchiotti et al. [@bib0070]   11       NA          NA          9             1             1    0   0   4
  Kapoor et al. [@bib0065]        13       9.3         3.3--18     9             0             4    0   0   5

NA indicates non available.

###### 

Clinical follow up of EMC in ten case series.

Table 3

  Case Series Author              Number of Cases   Clinical Follow Up                                    
  ------------------------------- ----------------- -------------------- ------- ---- ---- ---- ---- ---- ----
  Oliveira et al. [@bib0015]      23                23                   111.6   3    8    6    2    0    5
  Kawaguchi et al. [@bib0045]     42                42                   88.8    17   6    4    0    2    3
  Tateishi et al. [@bib0085]      19                19                   61      3    3    3    1    0    2
  Ehara et al. [@bib0010]         4                 4                    97.5    2    3    3    3    0    3
  Xiu-feng et al. [@bib0025]      9                 7                    93      4    2    2    0    0    2
  Drilon et al. [@bib0030]        86                86                   43.2    27   19   NA   NA   NA   14
  Ogura et al. [@bib0020]         23                23                   109     9    8    6    3    6    5
  Flucke et al. [@bib0055]        5                 4                    61      1    1    0    0    1    0
  Stacchiotti et al. [@bib0070]   11                10                   30      1    7    6    1    5    2
  Kapoor et al. [@bib0065]        13                12                   40.5    3    12   12   3    6    3

NA indicates non available.

###### 

Presence of ETV6-NTK3 gene rearrangement and immunohistochemical findings of EMC in five case series.

Table 4

  Case Series Author              Number   EWSR1-NR4A3   Immunohistochemical Findings                            
  ------------------------------- -------- ------------- ------------------------------ ---- ---- ---- ---- ---- ----
  Oliveira et al. [@bib0015]      23       NA            16                             13   5    3    2    NA   NA
  Tateishi et al. [@bib0085]      19       9             NA                             NA   NA   NA   NA   NA   NA
  Xiu-feng et al. [@bib0025]      9        NA            9                              2    0    6    0    7    NA
  Flucke et al. [@bib0055]        5        4             NA                             NA   2    2    NA   NA   NA
  Stacchiotti et al. [@bib0070]   11       11            NA                             1    7    3    NA   NA   9

NA indicates non available.

###### 

Treatment of EMC in seven case series.

Table 5

  Case Series Author              Number of Cases   Treatment                                     
  ------------------------------- ----------------- ----------- ---- --- ---- ---- ---- ---- ---- ----
  Oliveira et al. [@bib0015]      23                2           17   4   10   2    9    1    1    0
  Kawaguchi et al. [@bib0045]     42                3           30   5   6    1    5    7    0    6
  Tateishi et al. [@bib0085]      19                11          8    0   1    0    1    1    0    1
  Drilon et al. [@bib0030]        86                0           73   0   22   NA   NA   21   21   21
  Ogura et al. [@bib0020]         23                11          8    0   4    1    2    4    2    0
  Flucke et al. [@bib0055]        5                 2           2    0   0    0    0    0    0    0
  Stacchiotti et al. [@bib0070]   11                0           0    0   0    0    0    11   0    0

NA indicates non avaliable.

###### 

Reported cases of Pulmonary Extraskeletal Myxoid Chondrosarcoma.

Table 6

  Case Report Author                Publish Year   Age   Gender   Symptoms        Primary Site         Treatment                              Follow Up (Months)   Outcome
  --------------------------------- -------------- ----- -------- --------------- -------------------- -------------------------------------- -------------------- ----------
  Goetz et al. [@bib0095]           1992           66    F        Hemoptysis      Pleura               None                                   NA                   NA
  Ichimura et al. [@bib0100]        2004           35    M        None            Lung Parenchyma      Tumor Resection                        75                   Alive
  Zhou et al. [@bib0090]            2013           51    F        Severe Anemia   Left Upper Lobe      Lobectomy with Lymph Node Dissection   32                   Alive
  Gadabanahalli et al. [@bib0060]   2015           31    M        Dyspnea         Pulmonary arteries   Tumour excision                        9                    Deceased
  Present Case                      2016           69    M        Hemoptysis      Right Lower Lobe     Lobectomy with Lymph Node Dissection   3                    Alive

NA indicates non available.
